Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches

References

• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Banks J, Capstick T, et al. British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl2):ii1–ii64.
   PubMed Web of Science ®Google Scholar
• Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–134.
   PubMed Web of Science ®Google Scholar
• Adjemian J, Daniel-Wayman S, Ricotta E, et al. Epidemiology of nontuberculous mycobacteriosis. Semin Respir Crit Care Med. 2018;39:325–335.
   PubMed Web of Science ®Google Scholar
• Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review. Semin Respir Crit Care Med. 2018;39:336–342.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Koh WJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. J Korean Med Sci. 2016;31:649–659.
   PubMed Web of Science ®Google Scholar
• Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–976.
   PubMed Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–886.
   PubMed Web of Science ®Google Scholar
• Shah NM, Davidson JA, Anderson LF, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. BMC Infect Dis. 2016;16:195.
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, Wagner D, de Roux A, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerg Infect Dis. 2016;22:1102–1105.
   PubMed Web of Science ®Google Scholar
• Namkoong H, Kurashima A, Morimoto K, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22:1116–1117.
   PubMed Web of Science ®Google Scholar
• Ko RE, Moon SM, Ahn S, et al. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. J Korean Med Sci. 2018;33:e65.
   PubMed Web of Science ®Google Scholar
• Philley JV, Griffith DE. Treatment of slowly growing mycobacteria. Clin Chest Med. 2015;36:79–90.
   PubMed Web of Science ®Google Scholar
• Griffith DE. Treatment of Mycobacterium avium complex (MAC). Semin Respir Crit Care Med. 2018;39:351–361.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Koh WJ, Daley CL. Treatment of Mycobacterium avium complex pulmonary disease. Tuberc Respir Dis (Seoul). 2019;82:15–26.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis. 2014;18:1141–1148.
   PubMed Web of Science ®Google Scholar
• Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015;36:67–78.
   PubMed Web of Science ®Google Scholar
• Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus complex. Semin Respir Crit Care Med. 2018;39:362–376.
   PubMed Web of Science ®Google Scholar
• Basille D, Jounieaux V, Andrejak C. Treatment of other nontuberculous mycobacteria. Semin Respir Crit Care Med. 2018;39:377–382.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Ogbonna D, Deshpande D, et al. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother. 2017;72(Suppl 2):i3–i19.
   PubMedGoogle Scholar
• Kwak N, Park J, Kim E, et al. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017;65:1077–1084.
   PubMed Web of Science ®Google Scholar
• Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153:888–921.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928–934.
   PubMed Web of Science ®Google Scholar
• Kadota T, Matsui H, Hirose T, et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis. 2016;16:31.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13:1904–1911.
   PubMed Web of Science ®Google Scholar
• Moon SM, Park HY, Kim SY, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6758–6765.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15:149–161.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25:545–582.
   PubMed Web of Science ®Google Scholar
• Huh HJ, Kim SY, Jhun BW, et al. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect Genet Evol. 2018;S1567–S1348(1518):30784–30786. Epub ahead of print.
   Google Scholar
• Clinical Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 3rd ed. ( CLSI document No. M24). Wayne, PA: Clinical Laboratory Standards Institute; 2018.
   Google Scholar
• Clinical Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 1st ed. ( CLSI document No. M62). Wayne, PA: Clinical Laboratory Standards Institute; 2018.
   Google Scholar
• Ji B, Lounis N, Truffot-Pernot C, et al. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother. 1992;36:2839–2840.
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Nash KA, Petrofsky M, et al. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. J Infect Dis. 1996;174:1218–1222.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS clinical trials group protocol 157 Study Team. Ann Intern Med. 1994;121:905–911.
   PubMed Web of Science ®Google Scholar
• Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384–391.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392–398.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559–565.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeong BH, Jeon K, et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:797–802.
   PubMed Web of Science ®Google Scholar
• Jeong BH, Jeon K, Park HY, et al. Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6076–6083.
   PubMed Web of Science ®Google Scholar
• Deshpande D, Pasipanodya JG, Gumbo T. Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease. Antimicrob Agents Chemother. 2016;60:2157–2163.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866–872.
   PubMed Web of Science ®Google Scholar
• Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014;11:23–29.
   PubMedGoogle Scholar
• Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146:276–282.
   PubMed Web of Science ®Google Scholar
• Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191:96–103.
   PubMed Web of Science ®Google Scholar
• Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest. 2016;149:1285–1293.
   PubMed Web of Science ®Google Scholar
• Jhun BW, Kim SY, Moon SM, et al. Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2018;198:1322–1330.
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Nash K, Petrofsky M, et al. Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. Antimicrob Agents Chemother. 2000;44:2619–2622.
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130–138.
   PubMed Web of Science ®Google Scholar
• Kim OH, Kwon BS, Han M, et al. Association between duration of aminoglycoside treatment and outcome of cavitary Mycobacterium avium complex lung disease. Clin Infect Dis. 2019;68:1870–1876.
   PubMed Web of Science ®Google Scholar
• Ellender CM, Law DB, Thomson RM, et al. Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease. Respirology. 2016;21:357–362.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11:30–35.
   PubMedGoogle Scholar
• Yagi K, Ishii M, Namkoong H, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017;17:558.
   PubMed Web of Science ®Google Scholar
• Jhun BW, Yang B, Moon SM, et al. Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother. 2018;62:e00011.
   PubMed Web of Science ®Google Scholar
• Rose SJ, Neville ME, Gupta R, et al. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One. 2014;9:e108703.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814–823.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198:1559–1569.
   PubMed Web of Science ®Google Scholar
• Schön T, Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Int J Infect Dis. 2017;55:122–124.
   PubMed Web of Science ®Google Scholar
• Cho EH, Huh HJ, Song DJ, et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. J Infect Chemother. 2018;24:315–318.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57:2281–2285.
   PubMed Web of Science ®Google Scholar
• Jo KW, Kim S, Lee JY, et al. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother. 2014;20:602–606.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015;45:1177–1179.
   PubMed Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60:1361–1367.
   PubMed Web of Science ®Google Scholar
• Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003;124:1482–1486.
   PubMed Web of Science ®Google Scholar
• Martiniano SL, Wagner BD, Levin A, et al. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152:800–809.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med. 2014;20:280–286.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Koh WJ. Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opin Investig Drugs. 2016;25:183–193.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392:821–834.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Philley JV, Griffith DE, et al. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother. 2017;61:e01798.
   Web of Science ®Google Scholar
• Vesenbeckh S, Schonfeld N, Krieger D, et al. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections. Eur Respir J. 2017;49:1601969.
   PubMed Web of Science ®Google Scholar
• Pang Y, Zheng H, Tan Y, et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother. 2017;61:e02627.
   PubMed Web of Science ®Google Scholar
• Ruth MM, Sangen JJN, Remmers K, et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74:935–943.
   PubMed Web of Science ®Google Scholar
• Philley JV, Wallace RJ Jr., Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015;148:499–506.
   PubMed Web of Science ®Google Scholar
• Mitchell JD. Surgical management of pulmonary mycobacterial disease. Semin Respir Crit Care Med. 2018;39:392–398.
   PubMed Web of Science ®Google Scholar
• Kang HK, Park HY, Kim D, et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis. 2015;15:76.
   PubMed Web of Science ®Google Scholar
• Asakura T, Hayakawa N, Hasegawa N, et al. Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease. Clin Infect Dis. 2017;65:244–251.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51:3389–3394.
   PubMed Web of Science ®Google Scholar
• Gupta RS, Lo B, Son J. Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera. Front Microbiol. 2018;9:67.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Nakagawa T, Asami T, et al. Clinico-microbiological analysis of 121 patients with pulmonary Mycobacteroides abscessus complex disease in Japan – an NTM-JRC study with RIT. Respir Med. 2018;145:14–20.
   PubMed Web of Science ®Google Scholar
• Tan Y, Su B, Shu W, et al. Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013–2016. BMC Pulm Med. 2018;18:168.
   PubMed Web of Science ®Google Scholar
• Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896–902.
   PubMed Web of Science ®Google Scholar
• Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm (41),confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–1376.
   PubMed Web of Science ®Google Scholar
• Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother. 2011;55:775–781.
   PubMed Web of Science ®Google Scholar
• Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186:917–925.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Vasireddy S, Vasireddy R, et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015;53:1211–1215.
   PubMed Web of Science ®Google Scholar
• Diel R, Ringshausen F, Richter E, et al. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest. 2017;152:120–142.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Ogbonna D, Ferro BE, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother. 2017;61:e01206.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183:405–410.
   PubMed Web of Science ®Google Scholar
• Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med. 2014;108:1706–1712.
   PubMed Web of Science ®Google Scholar
• Park J, Cho J, Lee CH, et al. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017;64:301–308.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017;64:309–316.
   PubMed Web of Science ®Google Scholar
• Yang B, Jhun BW, Moon SM, et al. A clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61:e02052.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeong BH, Jeon K, et al. Oral macrolide therapy following short-term combination antibiotic treatment for Mycobacterium massiliense lung disease. Chest. 2016;150:1211–1221.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tsuyuguchi K, Suzuki K, et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. Int J Antimicrob Agents. 2013;42:226–231.
   PubMed Web of Science ®Google Scholar
• Shallom SJ, Moura NS, Olivier KN, et al. New real-time PCR assays for detection of inducible and acquired clarithromycin resistance in the Mycobacterium abscessus group. J Clin Microbiol. 2015;53:3430–3437.
   PubMed Web of Science ®Google Scholar
• Lee SH, Yoo HK, Kim SH, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med. 2014;34:31–37.
   PubMed Web of Science ®Google Scholar
• Mougari F, Amarsy R, Veziris N, et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother. 2016;71:2208–2212.
   PubMed Web of Science ®Google Scholar
• Cho EH, Huh HJ, Song DJ, et al. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagn Microbiol Infect Dis. 2019;93:107–111.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tsuyuguchi K, Kobayashi T, et al. Discrepancies between the genotypes and phenotypes of clarithromycin-resistant Mycobacterium abscessus complex. Int J Tuberc Lung Dis. 2018;22:413–418.
   PubMed Web of Science ®Google Scholar
• Nie W, Duan H, Huang H, et al. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics. Int J Infect Dis. 2014;25:170–174.
   PubMed Web of Science ®Google Scholar
• Li B, Yang S, Chu H, et al. Relationship between antibiotic susceptibility and genotype in Mycobacterium abscessus clinical isolates. Front Microbiol. 2017;8:1739.
   PubMed Web of Science ®Google Scholar
• Chew KL, Cheng JWS, Hudaa Osman N, et al. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. J Med Microbiol. 2017;66:1443–1447.
   PubMed Web of Science ®Google Scholar
• Carvalho NFG, Pavan F, Sato DN, et al. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41). J Antimicrob Chemother. 2018;73:862–866.
   PubMed Web of Science ®Google Scholar
• Chua KY, Bustamante A, Jelfs P, et al. Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales, Australia. Pathology. 2015;47:678–682.
   PubMed Web of Science ®Google Scholar
• Choi H, Jhun BW, Kim SY, et al. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. Diagn Microbiol Infect Dis. 2018;90:293–295.
   PubMed Web of Science ®Google Scholar
• Choi H, Kim SY, Kim DH, et al. Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61:e01146.
   PubMed Web of Science ®Google Scholar
• Choi H, Kim SY, Lee H, et al. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease. Antimicrob Agents Chemother. 2017;61:e02189.
   PubMed Web of Science ®Google Scholar
• Cowman S, Burns K, Benson S, et al. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect. 2016;72:324–331.
   PubMed Web of Science ®Google Scholar
• Kusuki M, Osawa K, Arikawa K, et al. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis. Diagn Microbiol Infect Dis. 2018;91:256–259.
   PubMed Web of Science ®Google Scholar
• Ananta P, Kham-Ngam I, Chetchotisakd P, et al. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand. PLoS One. 2018;13:e0208053.
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69:1945–1953.
   PubMed Web of Science ®Google Scholar
• Sfeir M, Walsh M, Rosa R, et al. Mycobacterium abscessus complex infections: a retrospective cohort study. Open Forum Infect Dis. 2018;5:ofy022.
   PubMed Web of Science ®Google Scholar
• Dupont C, Viljoen A, Thomas S, et al. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother. 2017;61:e01225.
   PubMed Web of Science ®Google Scholar
• Aguilar-Ayala DA, Cnockaert M, Andre E, et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol. 2017;66:1140–1143.
   PubMed Web of Science ®Google Scholar
• Li B, Ye M, Guo Q, et al. Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2018;62:e00175.
   PubMed Web of Science ®Google Scholar
• Obregón-Henao A, Arnett KA, Henao-Tamayo M, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother. 2015;59:6904–6912.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:e01919.
   PubMed Web of Science ®Google Scholar
• Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981;3:1028–1034.
   PubMedGoogle Scholar
• Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis. 1981;3:1035–1039.
   PubMedGoogle Scholar
• DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii infection: beyond 2018. Front Microbiol. 2018;9:2271.
   PubMed Web of Science ®Google Scholar
• Bakula Z, Modrzejewska M, Pennings L, et al. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii. Antimicrob Agents Chemother. 2018;62:e01788.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Ferro BE, Hoefsloot W, et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther. 2013;11:1065–1077.
   PubMed Web of Science ®Google Scholar
• Moon SM, Choe J, Jhun BW, et al. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med. 2019;148:37–42.
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18:736–743.
   PubMed Web of Science ®Google Scholar
• Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother. 2001;45:3056–3058.
   PubMed Web of Science ®Google Scholar